SEOUL, Oct. 28 (Yonhap) -- Yuhan Corp., a South Korean biopharmaceutical company, said Monday its third-quarter net profit ...

Yuhan-Kimberly, a joint venture between Korea’s Yuhan Corp. and America’s Kimberly Clark, has been chosen as one of the ...

Yuhan stands to potentially receive up to $1.25 billion in potential development and commercial milestone payments, along with tiered double-digit royalties on future net sales.

Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies. BioWorld Asia Deals ...

J INTS BIO will oversee the entire project, managing clinical trials to validate AI-based predictions and develop clinically ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Yuhan Li is Associate Director of Learning Design in the Center for Digital Innovation in Learning at Boston College. With nearly 8 years of experience supporting faculty teaching in higher education, ...

4 Women's 4 x 200m Freestyle Relay 7:47.96 3 Women's 4 x 200m Freestyle Relay, Heats 7:49.58 Q 2 Women's 4 x 200m Freestyle Relay, Heats, Heat 2 7:49.58 4 Women's 4 x 200m Freestyle Relay, Final 7 ...